AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With Sorafenib

NCT00467025 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

152

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Renal Cell Carcinoma

Interventions

DRUG: AMG 386
DRUG: Sorafenib
DRUG: AMG 386 placebo IV

Sponsor

Amgen